Cellectis H1 revenue falls to $11M, loss $39.6M
Cellectis’ amended 6-K adds iXBRL and confirms sharply lower H1 2026 revenue but a slightly reduced net loss, supported by strong cash and term deposits.
Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K/A
Rhea-AI Filing Summary
Cellectis S.A. (CLLS) filed an amended Form 6-K mainly to add iXBRL formatting, while reaffirming its unaudited results for the six months ended June 30, 2026. Revenue fell to $11.0 million from $27.4 million, largely due to lower activity under AstraZeneca collaboration research plans, while other income rose modestly from higher research tax credits.
Research and development expenses increased to $52.2 million and selling, general and administrative expenses to $11.3 million, driving an operating loss of $48.7 million versus $23.8 million a year earlier. A swing to a $9.2 million net financial gain from an $18.1 million loss, helped by fair value gains on EIB warrants and lower FX losses, narrowed the net loss slightly to $39.6 million ($0.39 per share). Cash and cash equivalents were $35.6 million and current financial assets (fixed-term deposits) $131.3 million, and the company states this liquidity should fund operations for at least 12 months on a going-concern basis.
Positive
- Net financial result improved by $27.3 million, from a $18.1 million loss to a $9.2 million gain, mainly due to fair value gains on EIB warrants and much lower foreign exchange losses.
- Net loss narrowed slightly to $39.6 million from $41.9 million despite higher operating expenses, helped by the stronger financial result.
- Liquidity remains substantial, with $35.6 million in cash and cash equivalents plus $131.3 million in current financial assets as of June 30, 2026, and management asserting at least 12 months of funding on a going-concern basis.
Negative
- Revenue declined about 60% to $11.0 million from $27.4 million, mainly reflecting lower activity and revenue recognition under AstraZeneca research plans.
- Operating loss roughly doubled to $48.7 million from $23.8 million, as higher R&D and SG&A spending more than offset revenue and other income.
- R&D expenses increased to $52.2 million from $45.0 million, and SG&A to $11.3 million from $9.8 million, indicating higher cost intensity during the period.
- Shareholders’ equity fell to $41.1 million from $75.9 million at December 31, 2025, reflecting continued losses and allocations of prior-period losses.
